MGRX Mangoceuticals, Inc. - 8-K

Item
7.01 Regulation FD Disclosure.

On
February 23, 2026, Mangoceuticals, Inc. (the “ Company ”, “ we ” and “ us ”) issued
a press release announcing new data from field trials and a controlled study regarding its proprietary and patented antiviral compound
MGX-0024, including zero respiratory-related mortality in approximately 29,000-bird commercial poultry field trials in India and prophylactic
benefits against H5N1 in a government-conducted challenge study.

The
press release is furnished as  Exhibit 99.1  to this Current Report on Form 8-K and incorporated into this  Item
7.01  by reference. The information in this  Item 7.01 , including  Exhibit 99.1 attached hereto, shall
not be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, except as expressly set forth by specific reference in such filing.

Item
9.01 Financial Statements and Exhibits.

(d)
Exhibits.

Exhibit
Number

Description
of Exhibit

99.1

Press Release dated February 23, 2026

104

Cover Page Interactive
Data File (embedded within the Inline XBRL document)

Forward-Looking
Statements

This
Current Report and the press release attached as  Exhibit 99.1  to this Current Report may contain forward-looking information
within the meaning of applicable securities laws (“ forward-looking statements ”). These forward-looking statements
represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements
that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,”
“intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target”
or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are
outside of the Company’s control, which could cause actual results to differ materially from the results expressed or implied in
the forward-looking statements. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties
and other important factors that may cause actual results, performance, or achievements to be materially different from any future results,
performance, or achievements expressed or implied by the forward-looking statements. The Company undertakes no obligation to publicly
update or revise any of the forward-looking statements, whether because of new information, future events or otherwise, made in the release
or presentation or in any of its SEC filings or public disclosures, except as provided by law. Consequently, you should not consider
any such list to be a complete set of all potential risks and uncertainties. More information on potential factors that could affect
the Company’s financial results is included from time to time in the “ Forward-Looking Statements ,” “ Risk
Factors ” and “ Management’s Discussion and Analysis of Financial Condition and Results of Operations ”
sections of the Company’s periodic and current filings with the SEC, including Form 10-Qs, Form 10-Ks and Form 8-Ks, filed with
the SEC and available at  www.sec.gov . Forward-looking statements speak only as of the date they are made.